BRAF V600M

CI-VAR-00004580Explore in graph →NP_001361187.1:p.Val640MetNM_001374258.1:c.1918G>AClinVar 44815 CIViC 1405 rs121913378

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma2
BRAF V600E AND BRAF V600M	Dabrafenib	Predictive	C	Supports Sensitivity Response	1	accepted	EID73 A single 66-year old male patient with advanced melanoma thought to have concomitant BRAF V600E and V600M mutations responded rapidly to dabrafenib. His shoulder lesion reduced by 60% after 1 week of … (full text at CIViC) PMID 23031422 · Ponti et al., 2012 · Open in CIViC	civic
BRAF V600M	BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID7631 In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
44815	Likely pathogenic	criteria provided, single submitter	1	Non-small cell lung carcinoma	somatic	2	May 09, 2012	clinvar